Median (IQR) exposure in subjects with target joints at the start point of the B-LONG study (subanalysis 3)
| Treatment group∗ . | WP (n = 41) . | Individualized IP (n = 13) . | Modified prophylaxis (n = 13) . |
|---|---|---|---|
| Average weekly dose, IU/kg | 46.2 (37.8-55.6) | 69.6 (46.7-73.2) | 62.1 (41.7-115.1) |
| Dosing interval, d | 7.0 (6.9-7.0) | 10.1 (9.9-13.1) | 6.4 (4.9-6.9) |
| Treatment group∗ . | WP (n = 41) . | Individualized IP (n = 13) . | Modified prophylaxis (n = 13) . |
|---|---|---|---|
| Average weekly dose, IU/kg | 46.2 (37.8-55.6) | 69.6 (46.7-73.2) | 62.1 (41.7-115.1) |
| Dosing interval, d | 7.0 (6.9-7.0) | 10.1 (9.9-13.1) | 6.4 (4.9-6.9) |
Subjects are included in each treatment regimen they participated in for the duration of time on that regimen and, as such, may appear in ≥1 treatment regimen.